Zymeworks (ZYME) Assets Average (2022 - 2026)
Zymeworks' (ZYME) quarterly Assets Average came in at $412.4 million in Q1 2026, down 7.19% year-on-year from $444.3 million in Q1 2025, and up 10.88% quarter-over-quarter from $371.9 million in Q4 2025.
Zymeworks (ZYME) Assets Average (2022 - 2026) Analysis & Trends
Zymeworks has disclosed Assets Average across 5 years of filings, most recently posting $412.4 million for Q1 2026.
- Assets Average for Q1 2026 came in at $412.4 million, down 7.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $412.4 million (down 7.19% YoY), and the FY2025 annual result was $404.8 million, down 22.45% from the prior year.
- Assets Average came in at $412.4 million for Q1 2026 at Zymeworks, up from $371.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $624.7 million in Q1 2023 to a low of $371.9 million in Q4 2025.
- The 5-year median for Assets Average is $488.3 million (2024), against an average of $498.2 million.
- Across the five-year window, Assets Average gained 19.84% in 2023 and decreased 22.02% in 2025, its largest moves.
- Zymeworks' Assets Average stood at $474.5 million in 2022, then increased by 19.84% to $568.6 million in 2023, then declined by 16.44% to $475.1 million in 2024, then retreated by 21.73% to $371.9 million in 2025, then rose by 10.88% to $412.4 million in 2026.
- The last three Assets Average figures came in at $412.4 million (Q1 2026), $371.9 million (Q4 2025), and $402.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 26.03 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 40.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 660.38 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 412.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 412.37 Mn |
| Dec 31, 2025 | 371.90 Mn |
| Sep 30, 2025 | 402.83 Mn |
| Jun 30, 2025 | 416.95 Mn |
| Mar 31, 2025 | 444.31 Mn |
| Dec 31, 2024 | 475.12 Mn |
| Sep 30, 2024 | 501.39 Mn |
| Jun 30, 2024 | 534.69 Mn |
| Mar 31, 2024 | 567.32 Mn |
| Dec 31, 2023 | 568.62 Mn |
| Sep 30, 2023 | 579.21 Mn |
| Jun 30, 2023 | 601.40 Mn |
| Mar 31, 2023 | 624.73 Mn |
| Dec 31, 2022 | 474.49 Mn |